Avisi Technologies has presented two-year follow-up data from its VITA clinical trial of the VisiPlate aqueous shunt at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans.
The investigational device is being developed as a surgical approach for lowering intraocular pressure in patients with open-angle glaucoma. VisiPlate is an ultrathin, multichannel aqueous shunt designed to drain aqueous humor from the anterior chamber of the eye.
Jonathan S. Myers, Director of the Glaucoma Service and Endowed Chair in Glaucoma at Wills Eye Hospital, presented the longer-term VITA findings during an AAO poster session on October 11. His presentation, “Long-Term Efficacy and Safety of a Novel, Ultrathin, Multichannel Aqueous Shunt in Patients With OAG,” followed the release of 12-month data from the study at AAO 2025.
VITA is a prospective, single-arm, multicenter, open-label clinical trial evaluating VisiPlate in patients with primary open-angle glaucoma. The study was conducted at three sites in South Africa, with the latest analysis extending follow-up to two years.
VisiPlate has been designed with multiple microchannels intended to maintain aqueous flow while reducing the risk of obstruction. The device is manufactured using a proprietary metamaterial and is designed to be considerably thinner than conventional glaucoma drainage implants.
Scarring and occlusion can limit the long-term performance of glaucoma drainage devices, making the interaction between implant design and the surrounding tissue an important consideration in the development of new surgical approaches. Avisi is investigating whether the VisiPlate design can support sustained aqueous drainage over longer periods.
Alongside the formal poster presentation, Avisi used AAO to host two sessions focused on the technology and its clinical development.
Myers presented an overview of the VITA two-year follow-up at the company’s exhibition booth on October 10. A second session brought together Avisi scientific advisors to discuss the device’s design and surgical technique, drawing on experience gained during the company’s ongoing US investigational device exemption study.
Participants included Eydie Miller-Ellis, President of the American Glaucoma Society, and Joseph Panarelli, with the discussion moderated by Sanjeev Kasthurirangan, Avisi’s Vice President of Clinical and Regulatory Affairs.
The company is continuing to evaluate VisiPlate as part of its US clinical development program. The device forms part of a wider pipeline that also includes a sustained intraocular drug-delivery platform and a suprachoroidal drainage device designed for use alongside cataract surgery.
The two-year VITA follow-up presented at AAO adds longer-term clinical observation to the early evidence being gathered around the ultrathin shunt as Avisi continues development of the technology.
